Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review

Ann Pharm Fr. 2022 Sep;80(5):617-634. doi: 10.1016/j.pharma.2022.01.007. Epub 2022 Jan 31.


Objectives: Beta-blockers have long been successfully used for the treatment of both supraventricular and ventricular arrhythmias. However, differences exist between their chemical structure, pharmacokinetic and pharmacodynamic properties (absorption, bioavailability, metabolism, hydrophilic or lipophilic character, selective or non-selective nature, the presence or absence of intrinsic sympathomimetic activity), which may confer different antiarrhythmic properties to different beta-blockers. The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and ventricular arrhythmias.

Material and methods: Using the keywords "bisoprolol" and "arrhythmias" or "atrial fibrillation" or "ventricular tachycardia" or "premature ventricular complexes" or "ventricular fibrillation", the Medline database was searched for articles in English or French until April 2020 assessing the role of bisoprolol in the treatment of arrhythmias. Data was then analyzed according to the type of arrhythmia treated and the quality of evidence using the GRADE approach.

Results: A total of 325 studies were identified, of which 28 were considered relevant to the current topic. Among these studies, 19 assessed the role of bisoprolol for the treatment of supraventricular arrhythmias, 8 its role in treating ventricular arrhythmias and 1 its role in supraventricular and ventricular arrhythmias. The quality of evidence varied from low (7 studies) to high (5 studies).

Conclusion: Current evidence exists supporting the use of bisoprolol for the treatment of supraventricular arrhythmias, especially for rate control during atrial fibrillation. Evidence also exists for its efficacy in the treatment of ventricular arrhythmias, both in primary and in secondary prevention.

Keywords: Arrhythmias; Arythmies; Arythmies ventriculaires; Atrial fibrillation; Beta-blockers; Bisoprolol; Bêtabloquants; Fibrillation auriculaire; Ventricular arrhythmias.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • Bisoprolol* / therapeutic use
  • Humans


  • Adrenergic beta-Antagonists
  • Bisoprolol